Status: Recruiting
A Phase 1 Study to Evaluate Safety and Efficacy of XER-001 (Amifostine for Nasoduodenal Delivery) in Combination With Sterotactic Body Radiotherapy for Treatment in Patients With Locally Advanced Pancreatic Cancer.
The purpose of this study is to assess the safety, tolerability and efficacy of XER-001 and identify a best dose for future studies.
Participants needed: 36
Trial details
Phase: Phase 1, Phase 2Age: 18+Biological sex: AllType: InterventionalSponsor: Xerient PharmaUpdated: May 1, 2026Locations: 4
Eligibility criteria
Cytologic or biopsy confirmed adenocarcinoma of the pancreas [+26]
Prior radiotherapy to the upper abdomen with overlap of. the anticipated SBRT fi... [+25]